摘要
目的探讨硼替佐米联合化疗治疗多发性骨髓瘤的临床效果。方法于2016年1月至2019年12月,选择70例多发性骨髓瘤病例为研究对象,根据随机双盲法将其分为对比组和研究组,各35例。对比组给予常规化疗方案进行治疗,研究组应用硼替佐米联合化疗方案进行治疗。比较两组的治疗效果、中位起效时间、生活质量及不良反应发生情况。结果研究组的临床治疗总有效率为85.71%,显著高于对比组的62.86%,差异具有统计学意义(P<0.05);研究组的中位起效时间短于对比组,生活质量评分低于对比组,差异具有统计学意义(P<0.05)。研究组的不良反应总发生率为20.00%,略高于对比组的17.14%,但差异不具有统计学意义(P>0.05)。结论硼替佐米联合化疗方案治疗多发性骨髓瘤患者,能够进一步提升临床治疗效果,且不良反应少、疗效高、安全性可靠。
Objective To explore the clinical effect of bortezomib combined with chemotherapy in the treatment of multiple myeloma.Methods From January 2016 to December 2019,seventy patients with multiple myeloma were selected as the study objects.According to the randomized double-blind method,the patients were divided into contrast group and study group,with 35 cases in each group.The contrast group was treated with conventional chemotherapy,and the study group was treated with bortezomib combined with chemotherapy scheme.The treatment effect,median onset time,quality of life and adverse reactions of the two groups were compared.Results The total effective rate of clinical treatment in the study group was 85.71%,which was significantly higher than 62.86%in the contrast group,and the difference was statistically significant(P<0.05).The median onset time of the study group was shorter than that of the contrast group,and the quality of life score was lower than that of the contrast group,the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the study group was 20.00%,which was slightly higher than 17.14%in the contrast group,but the difference was not statistically significant(P>0.05).Conclusion Bortezomib combined with chemotherapy scheme in the treatment of patients with multiple myeloma can further improve the clinical treatment effect,with fewer adverse reactions,high efficacy,and reliable safety.
作者
丁艳
DING Yan(Hematology Department,Yancheng No.1 People's Hospital,Yancheng 224000,China)
出处
《临床医学研究与实践》
2020年第22期23-25,共3页
Clinical Research and Practice
